The indication for the prolonged release melatonin product Circadin has been extended to up to 13 weeks in patients with primary insomnia.
Circadin was previously available as a three week course of treatment, but is now approved for longer use in patients with primary insomnia, aged 55 years or over.
It is intended to help restore natural sleep rhythm by increasing levels of melatonin.
Nursing Times Learning
Subscribers get five FREE learning units and non-subscribers can access each learning unit for £10 + VAT.
Click on the topics below to get started: